Christopeit, Maximilian http://orcid.org/0000-0003-4627-0412
Schmidt-Hieber, Martin
Sprute, Rosanne
Buchheidt, Dieter
Hentrich, Marcus
Karthaus, Meinolf
Penack, Olaf
Ruhnke, Markus
Weissinger, Florian
Cornely, Oliver A.
Maschmeyer, Georg
Article History
Received: 6 July 2020
Accepted: 3 October 2020
First Online: 20 October 2020
Compliance with ethical standards
:
: Maximilian Christopeit reports personal fees from Merck/MSD, GILEAD, Basilea, Pfizer, IQONE, Shionogi, non-financial support and other from Robert-Koch-Institut during the conduct of the study; others from Celgene, personal fees from JAZZ, Stemline, outside the submitted work.Martin Schmidt-Hieber has received financial support for educational meetings at the Carl-Thiem-Klinikum, Cottbus/Germany from the following companies: Janssen-Cilag, Takeda, Novartis, Pfizer, Roche, Vifor and Celgene.Rosanne Sprute declares that she has no conflict of interest.Dieter Buchheidt reports personal fees from Gilead Sciences, Pfizer and Merck Sharp & Dohme/Merck, outside the submitted work.Marcus Hentrich declares that he has no conflict of interest.Meinolf Karthaus reports personal fees from Riemser, Roche, Celgene and Servier, outside the submitted work.Olaf Penack reports personal fees from Astellas, Merck/MSD, Shionogi, Pfizer, Omeros and grants from Incyte, outside the submitted work.Markus Ruhnke declares that he has no conflict of interest.Florian Weissinger reports personal fees from Roche, Novartis, Sanofi, Janssen and Pfizer, outside the submitted work.Oliver A. Cornely is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy—CECAD, EXC 2030—390661388 and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck/MSD, Pfizer and Scynexis; a consultant to Actelion, Allecra Therapeutics, Al-Jazeera Pharmaceuticals, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini Ricerche, Merck/MSD, Mylan Pharmaceuticals, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Roche Diagnostics Scynexis, Seres Therapeutics, Tetraphase and Vical; and received lecture honoraria from Astellas, Basilea, Gilead, Grupo Biotoscana, Merck/MSD and Pfizer.Georg Maschmeyer reports personal fees from Gilead, Merck-Serono, Astra Zeneca and AMGEN and personal fees and non-financial support from Janssen Cilag, outside the submitted work.
: This article does not contain any studies with human participants or animals performed by any of the authors.